Discover

Biotech & Pharma Innovation

Drug developers from clinical to commercial.

Biotech and pharma pair binary clinical risk with genuine, life-changing innovation. This collection spans biotechnology and drug manufacturers — from clinical-stage developers to commercial-scale pharma — ranked by market cap.

1426 stocksSorted by market capUpdated 16 Jul 2026

Why it matters

Drug developers from clinical to commercial. This group spans defensive demand, consumer behaviour, rates exposure and innovation, so business-model quality matters more than the label.

What to check next

Compare pricing power, repeat demand, margins, regulatory risk and the sensitivity of each company to interest rates or consumer weakness.

Main risk

A theme can hide very different risk profiles: biotech, insurers, online retail and property all respond to different drivers.

Showing the 40 largest of 1426 — sort or filter to explore the rest.

Company	Market Cap	Reward	Risk	Yield
Eli Lilly and CompanyLLY	$970.6B	—	—	0.6%
Johnson & JohnsonJNJ	$590.8B	—	—	2.1%
Roche Holding AGRHHBF	$394.8B	—	—	2.0%
Roche Holding AG ParticipationRHHVF	$386.9B	—	—	2.1%
AbbVie IncABBV	$356.5B	—	—	3.3%
Novartis AG ADRNVS	$322.5B	—	—	2.9%
Merck & Company IncMRK	$305.9B	—	—	2.6%
AstraZeneca PLCAZN	$289.4B	—	—	1.7%
Gilead Sciences IncGILD	$182.5B	—	—	2.1%
Amgen IncAMGN	$182.2B	—	—	2.8%
Novo Nordisk A/SNVO	$169.6B	—	—	4.9%
Pfizer IncPFE	$154.0B	—	—	6.3%
Vertex Pharmaceuticals IncVRTX	$126.2B	—	—	—
GlaxoSmithKline PLC ADRGSK	$119.5B	—	—	3.0%
GSK plcGLAXF	$118.0B	—	—	2.2%
Bristol-Myers Squibb CompanyBMY	$117.6B	—	—	4.3%
Sanofi ADRSNY	$117.5B	—	—	8.5%
Chugai Pharmaceutical Co Ltd ADRCHGCY	$109.3B	—	—	1.9%
Regeneron Pharmaceuticals IncREGN	$82.6B	—	—	0.5%
Merck KGaA ADRMKKGY	$65.0B	—	—	7.4%
CSL LimitedCMXHF	$63.5B	—	—	2.4%
MERCK Kommanditgesellschaft auf AktienMKGAF	$63.4B	—	—	1.5%
Takeda Pharmaceutical Co Ltd ADRTAK	$59.2B	—	—	3.5%
UCB SAUCBJF	$58.1B	—	—	0.0%
Zoetis IncZTS	$57.8B	—	—	1.5%
Teva Pharmaceutical Industries LimitedTEVJF	$52.1B	—	—	—
argenx NV ADRARGX	$48.5B	—	—	—
Haleon plcHLN	$46.5B	—	—	0.6%
GALDERMA GROUP AGGALDY	$44.6B	—	—	0.4%
Bayer AG PKBAYRY	$41.4B	—	—	1.0%
Bayer AGBAYZF	$41.4B	—	—	0.3%
Alnylam Pharmaceuticals IncALNY	$40.2B	—	—	—
Teva Pharma Industries Ltd ADRTEVA	$39.4B	—	—	—
BeiGene, Ltd.ONC	$39.0B	—	—	—
Sandoz Group AGSDZXF	$38.6B	—	—	1.1%
Otsuka Holdings Co Ltd ADROTSKY	$36.6B	—	—	1.3%
Daiichi Sankyo Co Ltd ADRDSNKY	$36.1B	—	—	2.4%
Insmed IncINSM	$31.7B	—	—	—
Biogen IncBIIB	$28.5B	—	—	—
Hansoh Pharmaceutical Group Company LimitedHNSPF	$28.3B	—	—	7.6%

Eli Lilly and CompanyLLY · $970.6B
Reward—Risk—Yield0.6%
Johnson & JohnsonJNJ · $590.8B
Reward—Risk—Yield2.1%
Roche Holding AGRHHBF · $394.8B
Reward—Risk—Yield2.0%
Roche Holding AG ParticipationRHHVF · $386.9B
Reward—Risk—Yield2.1%
AbbVie IncABBV · $356.5B
Reward—Risk—Yield3.3%
Novartis AG ADRNVS · $322.5B
Reward—Risk—Yield2.9%
Merck & Company IncMRK · $305.9B
Reward—Risk—Yield2.6%
AstraZeneca PLCAZN · $289.4B
Reward—Risk—Yield1.7%
Gilead Sciences IncGILD · $182.5B
Reward—Risk—Yield2.1%
Amgen IncAMGN · $182.2B
Reward—Risk—Yield2.8%
Novo Nordisk A/SNVO · $169.6B
Reward—Risk—Yield4.9%
Pfizer IncPFE · $154.0B
Reward—Risk—Yield6.3%
Vertex Pharmaceuticals IncVRTX · $126.2B
Reward—Risk—
GlaxoSmithKline PLC ADRGSK · $119.5B
Reward—Risk—Yield3.0%
GSK plcGLAXF · $118.0B
Reward—Risk—Yield2.2%
Bristol-Myers Squibb CompanyBMY · $117.6B
Reward—Risk—Yield4.3%
Sanofi ADRSNY · $117.5B
Reward—Risk—Yield8.5%
Chugai Pharmaceutical Co Ltd ADRCHGCY · $109.3B
Reward—Risk—Yield1.9%
Regeneron Pharmaceuticals IncREGN · $82.6B
Reward—Risk—Yield0.5%
Merck KGaA ADRMKKGY · $65.0B
Reward—Risk—Yield7.4%
CSL LimitedCMXHF · $63.5B
Reward—Risk—Yield2.4%
MERCK Kommanditgesellschaft auf AktienMKGAF · $63.4B
Reward—Risk—Yield1.5%
Takeda Pharmaceutical Co Ltd ADRTAK · $59.2B
Reward—Risk—Yield3.5%
UCB SAUCBJF · $58.1B
Reward—Risk—Yield0.0%
Zoetis IncZTS · $57.8B
Reward—Risk—Yield1.5%
Teva Pharmaceutical Industries LimitedTEVJF · $52.1B
Reward—Risk—
argenx NV ADRARGX · $48.5B
Reward—Risk—
Haleon plcHLN · $46.5B
Reward—Risk—Yield0.6%
GALDERMA GROUP AGGALDY · $44.6B
Reward—Risk—Yield0.4%
Bayer AG PKBAYRY · $41.4B
Reward—Risk—Yield1.0%
Bayer AGBAYZF · $41.4B
Reward—Risk—Yield0.3%
Alnylam Pharmaceuticals IncALNY · $40.2B
Reward—Risk—
Teva Pharma Industries Ltd ADRTEVA · $39.4B
Reward—Risk—
BeiGene, Ltd.ONC · $39.0B
Reward—Risk—
Sandoz Group AGSDZXF · $38.6B
Reward—Risk—Yield1.1%
Otsuka Holdings Co Ltd ADROTSKY · $36.6B
Reward—Risk—Yield1.3%
Daiichi Sankyo Co Ltd ADRDSNKY · $36.1B
Reward—Risk—Yield2.4%
Insmed IncINSM · $31.7B
Reward—Risk—
Biogen IncBIIB · $28.5B
Reward—Risk—
Hansoh Pharmaceutical Group Company LimitedHNSPF · $28.3B
Reward—Risk—Yield7.6%

Frequently asked questions

What is the Biotech & Pharma Innovation collection?

Drug developers from clinical to commercial. It currently holds 1426 stocks, each rated by Openbook's Reward and Risk scores. Biotech and pharma pair binary clinical risk with genuine, life-changing innovation.

How are Biotech & Pharma Innovation stocks selected?

Constituents are chosen by a rules-based screen over the full UK and US common-stock universe, then ranked by market capitalisation.

How often is the Biotech & Pharma Innovation list updated?

It is rebuilt from live market data, so the constituents and their rankings update as prices and company fundamentals change — there is no fixed, hand-edited list.

How should I use the Reward and Risk ratings?

Openbook's Reward rating combines a stock's growth, momentum, profitability and valuation into a single 0–100 score, and the Risk rating scores financial strength, volatility and size. Use them to compare names within this theme — broadly, a higher Reward alongside a lower Risk is more attractive. They are quantitative research signals, not investment advice.

Openbook Reward and Risk ratings and factor scores are quantitative signals for research, not investment advice. Data may be delayed. Some US-listed names carry partial factor coverage.